<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Heat shock proteins (<z:chebi fb="24" ids="50430">HSPs</z:chebi>) are necessary for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell survival </plain></SENT>
<SENT sid="1" pm="."><plain>We identified a mutant of HSP110 (HSP110ΔE9) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> showing microsatellite instability (MSI <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), generated from an aberrantly spliced <z:chebi fb="2" ids="33699">mRNA</z:chebi> and lacking the HSP110 substrate-binding domain </plain></SENT>
<SENT sid="2" pm="."><plain>This mutant was expressed at variable levels in almost <z:hpo ids='HP_0000001'>all</z:hpo> MSI <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> tested </plain></SENT>
<SENT sid="3" pm="."><plain>HSP110ΔE9 impaired both the <z:mpath ids='MPATH_458'>normal</z:mpath> cellular localization of HSP110 and its interaction with other <z:chebi fb="24" ids="50430">HSPs</z:chebi>, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner </plain></SENT>
<SENT sid="4" pm="."><plain>HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, which are routinely prescribed in the adjuvant treatment of people with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The survival and response to chemotherapy of subjects with MSI <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> was associated with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> expression level of HSP110ΔE9 </plain></SENT>
<SENT sid="6" pm="."><plain>HSP110 may thus constitute a major determinant for both prognosis and treatment response in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>